Loading...
Loading...
Quest
Diagnostics
DGX, the world's leading diagnostic information services
company, and Hologic, Inc. (Hologic)
HOLX, a leading developer,
manufacturer and supplier of premium diagnostics products, medical imaging
systems and surgical products, with an emphasis on serving the healthcare
needs of women, announced today that they have entered into a strategic
alliance to more broadly offer testing based on Hologic's APTIMA family of
products, as well as to co-develop and promote advanced diagnostic solutions
to improve women's health.
"This alliance will enhance the ability of Quest Diagnostics to deliver
state-of-the-art testing methods and specialized expertise in women's health
diagnostic information services," said Steve Rusckowski, President and Chief
Executive Officer, Quest Diagnostics. "It builds on our long-standing
successful relationship with Hologic to lead the way in delivering solutions
that address the clinical challenges facing obstetricians and gynecologists in
treating women. This collaboration also promises to increase the range of
capabilities for advancing the health of women for both companies."
"This collaboration represents a potentially important new chapter in women's
health diagnostics," said Rob Cascella, Hologic's President and Chief
Executive Officer. "Quest Diagnostics' strong capabilities in diagnostic
information services and laboratory and interpretive consulting, when combined
with Hologic's technical expertise and product excellence, holds the potential
for us to develop new capabilities for serving unmet clinical needs for women
in other areas of cancer detection."
Under a non-exclusive agreement with an initial term of five years, the
companies will focus primarily on clinical areas critical to the health of
women. Quest Diagnostics will transition to a broader offering of services
based on Hologic's APTIMA family of products, which includes FDA-approved or
cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea and trichomonas
vaginalis. In addition, Quest Diagnostics will continue to utilize Hologic's
leading line of ThinPrep liquid-based cytology products.
Quest Diagnostics will also continue to offer Hologic's APTIMA HPV mRNA-based
assay nationally. Unlike other FDA-approved, DNA-based HPV tests, the APTIMA
HPV assay detects messenger RNA over-expressed from two viral oncogenes that
are integral to the development of cervical cancer. Hologic's APTIMA HPV assay
detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in
cervical specimens (refer to package insert for other indications and
limitations).
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in